Your AI-Trained Oncology Knowledge Connection!
Today’s electronic medical records allow providers to have accurate, up-to-date, and complete information, provide quicker access than a physical file, improve security and privacy, improve patient communication, enable safer prescriptions, and even cut costs
Using next-generation sequencing to help inform treatment options is growing in frequency, but the results can be difficult to interpret and implement in clinical practice.
In acute myeloid leukemia, ongoing clinical trials are exploring the potential of this checkpoint alone or as part of a dual immunotherapy regimen.
Much has changed in the understanding and treatment of urothelial cancer and questions are addressed in the updated ESMO clinical practice guidelines.
There are still a lot of things that are ongoing, and the myeloma field is evolving with new treatments, according to Mark Bustoros, MBBCh.
For localized colorectal cancer, the use of circulating tumor tDNA for both quantitative and qualitative detection can inform the risk of recurrence and metastatic dissemination.
In an interview with Lt Col Yovanni Casablanca, MD, discussed the incorporation of new treatments into the cervical cancer paradigm and provided insight into the necessity of inclusive research with novel therapies.
Neoadjuvant treatment with pembrolizumab, paclitaxel, and cisplatin achieved encouraging tumor responses in patients with locally advanced resectable esophageal squamous cell carcinoma.
Positive phase 1 results of TQ-B2450 combined with anlotinib have lead to a phase 3 study of the combination versus pembrolizumab in patient with PD-L1 positive advanced non–small cell lung cancer.
Findings from the phase 1/2 IPH2201-203 trial support the statement that monalizumab, cetuximab, and durvalumab show promising activity in patients with recurrent squamous cell carcinoma of the head and neck.
Considering later lines of treatment such as chimeric antigen receptor T-cell therapy, make it difficult for chimeric antigen receptor T-cell therapy to find its optimal place in the armamentarium.
Advances in the field have also led to the recognition of other clinical challenges, including unforeseen observations and complications associated with choosing the sequencing of appropriate therapeutic interventions as well as the management of drug-related complications.
According to Robert L. Ferris, MD, PhD, there is a steady pace of drug development for head and neck cancers despite modest findings with durvalumab triplet.
